PCSK9

There are 48 papers on PCSK9 in aging research: 9 trials and 18 observational studies in people, 9 in animals, 1 in cells, 10 reviews. The newest story, Nov 12, 2026: “Compact gene editor enables efficient DNA editing in mice”.

Biomarker

48 papers study it421 more mention it40 findings

154 new papers in 30 daysSee all 469 papers on PCSK9

At a glance

A human study links PCSK9 with lower Alzheimer's disease risk in APOE ε4 noncarriers, but finds no clear link in carriers. Another links higher PCSK9 with lower cardiovascular risk in men and higher risk in women. Human studies also associate PCSK9 with older age in men and postmenopausal status in women.

40 findings in 21 papers from 2014 to 2026, 5 of them since June 2026

“Higher plasma PCSK9 protein levels were associated with a lower risk of AD (HR [95%CI]: 0.74 [0.58, 0.94]; p = 0.01) in APOE ε4 noncarriers”
Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype-Dependent Manner: A Prospective Cohort StudyHealth science reports2026doi:10.1002/hsr2.71810
  • Human trial9
  • Humans18
  • Animals9
  • Cells1
  • In silico1

Interventions

11

Caloric restriction

downin humans2

2 studies
  1. Caloric restriction decreases PCSK9 in humans (combined with FATmax exercise; REE and REE + PA67% groups).

    “Serum PCSK9 was significantly decreased in the REE and the REE + PA 67% groups”

    Human trialcombined with FATmax exercise; REE and REE + PA67% groups4 weeks

    Optimal calorie restriction threshold: effect of FATmax exercise combined with different proportions of calorie restriction on hypercholesterolemia

    Frontiers in physiology

  2. Caloric restriction decreases PCSK9 in morbidly obese women (normalized by day 3).

    “Already after 3 days on a low-calorie diet, BA and cholesterol synthesis and serum BA and PCSK9 levels normalized”

    Human trialin morbidly obese women800-1100 kcal day−13 daysfemalesn = 10

    Acute caloric restriction counteracts hepatic bile acid and cholesterol deficiency in morbid obesity

    Journal of internal medicine

More on Caloric restriction

Biliopancreatic diversion with duodenal switch

downin humans1upin humans1

1 study
  1. Biliopancreatic diversion with duodenal switch decreases PCSK9 in humans (chronic, 12 months after surgery) (-9.5% vs baseline (217.6 ng/mL)).

    “decreased 9.5% at 12 months compared with baseline (217.6 ± 43.0 ng/mL; P < 0,0001)”

    Human trialchronic, 12 months after surgery12 months

    Acute and Chronic Impact of Bariatric Surgery on Plasma LDL Cholesterol and PCSK9 Levels in Patients With Severe Obesity

    The Journal of clinical endocrinology and metabolism

  2. Biliopancreatic diversion with duodenal switch increases PCSK9 in humans (acute, 24 hours after surgery) (+13.4% (248.7 to 269.7 ng/mL)).

    “PCSK9 levels increased 13.4% after 24 hours (248.7 ± 64.8 to 269.7 ± 63.8 ng/mL; P = 0,02)”

    Human trialacute, 24 hours after surgery24 hours

    Acute and Chronic Impact of Bariatric Surgery on Plasma LDL Cholesterol and PCSK9 Levels in Patients With Severe Obesity

    The Journal of clinical endocrinology and metabolism

More on Biliopancreatic diversion with duodenal switch

SYH2053

downin humans1

1 study
  1. SYH2053 decreases PCSK9 in humans (Primary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparison) (-91.50% versus placebo (95% CI -99.80 to -83.21; p < 0.0001)).

    “At Day 180, SYH2053-300 mg group exhibited the numerically greatest reductions in LDL-C and PCSK9 among the five groups”

    Human trialPrimary hypercholesterolemia or mixed dyslipidemia; placebo-adjusted comparisoninjection300 mg180 days

    Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial

    ESC Congress 2026 abstract

More on SYH2053

Gene-editing

downin humans1

1 study
  1. Gene-editing decreases PCSK9 in humans (early phase clinical evaluation).

    “initial reports demonstrating favorable reductions in ANGPTL3 and proprotein convertase subtilisin kexin type 9”

    Reviewearly phase clinical evaluation

    CRISPR therapy for dyslipidemia

    Current opinion in lipidology

More on Gene-editing

Xiaoyao san

downin mice1

1 study
  1. Xiaoyao san decreases PCSK9 in ovariectomized ApoE−/− mice on a high-fat and high-fructose diet.

    “XYS reduced hepatic/serum PCSK9 and upregulated LDLR, attenuating dyslipidemia and atherosclerosis.”

    Animalsin ovariectomized ApoE−/− mice on a high-fat and high-fructose dietliver14 weeks

    Xiaoyao San attenuates postmenopausal atherosclerosis via ERα-mediated suppression of hepatic PCSK9 transcription

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on Xiaoyao san

Hypolipidemic agents

upin humans1

1 study
  1. Hypolipidemic agents increase PCSK9 in humans (WMD 23.25 ng/mL, 95% CI 17.00–29.50, p < 0.01).

    “Results indicate a significant increase in plasma PCSK9 levels following treatment with conventional lipid-lowering drugs (weighted mean difference: 23.25 ng/mL; 95% confidence interval: 17.00, 29.50; p < 0.01”

    Reviewat least 2 weeksn = 1,313

    Impact of conventional lipid-lowering therapy on circulating levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis of randomised controlled trials

    Diabetes, obesity & metabolism

More on Hypolipidemic agents

CRISPR off-ee

downin mice1

1 study
  1. CRISPR off-ee decreases PCSK9 in mice (targeting Pcsk9) (∼83.2% reduction, persisting for at least 180 days).

    “resulted in an ∼83.2% reduction in circulating PCSK9 levels”

    Animalstargeting Pcsk9optimized OFF-EE V2 mRNA with selected guide RNAs in lipid nanoparticlessingle administrationat least 180 days

    mRNA-engineered CRISPR-Cas epigenetic editors enable durable and efficient gene silencing in vivo

    Innovation (Cambridge (Mass.))

More on CRISPR off-ee

Cold water immersion

downin humans1

1 study
  1. Cold water immersion decreases PCSK9 in humans (repeated CWI compared with initial values) (significant decrease, p = 0.01).

    “PCSK9 (p = 0.01) and hsCRP (p = 0.01) showed a significant decrease when compared to initial values.”

    Human trialrepeated CWI compared with initial valueswithout neoprene equipmentthree times per week for 7-10 min5 monthsn = 28

    Effect of repeatedly applied cold water immersion on subclinical atherosclerosis, inflammation, fat accumulation and lipid profile parameters of volunteers

    Wiener klinische Wochenschrift

More on Cold water immersion

Intermittent fasting

upin humans1

1 study
  1. Intermittent fasting is linked with higher PCSK9 in humans (metabolically healthy obese adults, end of Ramadan compared with pre-fasting).

    “We found significant (p < 0.05) increases in serum levels of PCSK9, serum insulin, insulin resistance, and leptin at the end of Ramadan compared with pre-fasting levels.”

    Humansmetabolically healthy obese adults, end of Ramadan compared with pre-fastingn = 55

    Ramadan Intermittent Fasting Is Associated with Changes in Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Metabolically Healthy Obese Subjects

    Medicina (Kaunas, Lithuania)

More on Intermittent fasting

Statins

upin humans1

1 study
  1. Statins are linked with higher PCSK9 in humans (compared with no statin use).

    “Statin therapy significantly increased the PCSK9 levels in NGT, PreDM and T2D groups compared with subjects with no statins.”

    Humanscompared with no statin use

    PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy

    Journal of clinical medicine

More on Statins

Berberine + red yeast rice + chitosan + coenzyme Q10

no changein humans1

1 study
  1. Berberine + red yeast rice + chitosan + coenzyme Q10 showed no clear effect on PCSK9 in humans.

    “No significant increase in PCSK9 levels were observed during the follow-up (GLM p = 0.092) or between treatments (GLM p = 0.244; d).”

    Human trialonce daily12 weeksn = 39

    Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study

    International journal of molecular sciences

More on Berberine + red yeast rice + chitosan + coenzyme Q10

Effects

3

Cardiovascular disease

no changein humans1HR 0.57

1 study
  1. PCSK9 was not clearly linked with cardiovascular disease in humans (highest versus lowest level of serum PCSK9) (HR 0.57 (95% CI 0.27–1.20), highest vs lowest level).

    “Compared with participants with the lowest level of serum PCSK9, those with the highest level had a similar risk of CVD in males (HR=0.57, 95% CI: 0.27-1.20, P = 0.138)”

    Humanshighest versus lowest level of serum PCSK9median follow-up 6.7 yearsmalesn = 1,876

    Circulating PCSK9 as a sex-stratified predictor in primary prevention of cardiovascular disease: Insights from a prospective cohort study in Chinese adults

    American journal of preventive cardiology

More on Cardiovascular disease

Alzheimer's disease

no changein humans1

1 study
  1. PCSK9 was not clearly linked with Alzheimer's disease in APOE ε4 carriers.

    “PCSK9 levels were not significantly associated with AD risk in APOE ε4 carriers”

    Humansin APOE ε4 carriers

    Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype-Dependent Manner: A Prospective Cohort Study

    Health science reports

More on Alzheimer's disease

Lipoprotein

upin humans1

1 study
  1. PCSK9 is linked with higher lipoprotein in humans across PCSK9 tertiles; HeFH group only, not controls.

    “the Lp(a) concentration and percentage of Lp(a)≥300mg/L were increased by PCSK9 tertiles in HeFH group (both p<0.05)”

    Humansacross PCSK9 tertiles; HeFH group only, not controlsPCSK9 tertilesn = 255

    Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study

    Metabolism: clinical and experimental

More on Lipoprotein

Upstream

2

Glucose tolerance status

no changein humans1

1 study
  1. glucose tolerance status was not clearly linked with PCSK9 in humans (comparing normal glucose tolerance, prediabetes and type 2 diabetes groups).

    “PCSK9 plasma levels did not significantly differ between the three groups.”

    Humanscomparing normal glucose tolerance, prediabetes and type 2 diabetes groups

    PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy

    Journal of clinical medicine

Heterozygous familial hypercholesterolemia

upin humans1

1 study
  1. Heterozygous familial hypercholesterolemia is linked with higher PCSK9 in humans.

    “Both plasma PCSK9 and Lp(a) levels were significantly higher in patients with HeFH compared to control group (p<0.001).”

    Humansn = 255

    Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study

    Metabolism: clinical and experimental

More on Heterozygous familial hypercholesterolemia

Associations

19

Lipoprotein

upin humans2

2 studies
  1. Lipoprotein is associated with PCSK9 in normal control group (G3) (r = 0.366, p = 0.019).

    “a weak positive correlation was found in the normal control group (G3; r = 0.366, p = 0.019).”

    Humansin normal control group (G3)n = 69

    Relationship between lipoprotein(a) and PCSK9 in angiogram-proven premature coronary artery disease in an Asian cohort

    Scientific reports

  2. Lipoprotein is associated with PCSK9 in HeFH group; not in controls (r=0.254).

    “In partial correlation analysis, Lp(a) was associated with PCSK9 (r=0.254, p<0.001) in HeFH group but not in control”

    Humansin HeFH group; not in controlsn = 255

    Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study

    Metabolism: clinical and experimental

More on Lipoprotein

Female sex

upin humans2

2 studies
  1. female sex is associated with PCSK9 in humans.

    “Endogenous PCSK9 levels were higher in female (p = 0.005).”

    Humansfemales

    Sex-Specific Association of Endogenous PCSK9 With Memory Function in Elderly Subjects at High Cardiovascular Risk

    Frontiers in aging neuroscience

  2. Female sex is associated with PCSK9 in humans (Healthy volunteers; females compared with males) (10% higher in females than males).

    “The mean levels of PCSK9 were 10% higher in females than in males (P < 0.05).”

    HumansHealthy volunteers; females compared with malesplasma

    Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol

    Journal of lipid research

Cardiovascular disease

downin humans1upin humans1HR 0.71–1.38

1 study
  1. PCSK9 is linked with a lower risk of cardiovascular disease in humans (per log-PCSK9, independent of conventional risk factors) (HR 0.71 (95% CI 0.52–0.96) per log-PCSK9).

    “A higher level of serum PCSK9 at baseline was associated with a lower risk of CVD in males (HR=0.71, 95%CI: 0.52-0.96, P = 0.027 for log-PCSK9)”

    Humansper log-PCSK9, independent of conventional risk factorsmedian follow-up 6.7 yearsmalesn = 1,876

    Circulating PCSK9 as a sex-stratified predictor in primary prevention of cardiovascular disease: Insights from a prospective cohort study in Chinese adults

    American journal of preventive cardiology

  2. PCSK9 is linked with a higher risk of cardiovascular disease in humans (per log-PCSK9, independent of conventional risk factors) (HR 1.38 (95% CI 1.03–1.84) per log-PCSK9).

    “but with a higher risk of CVD in females (HR=1.38, 95%CI: 1.03-1.84, P = 0.032 for log-PCSK9)”

    Humansper log-PCSK9, independent of conventional risk factorsmedian follow-up 6.7 yearsfemalesn = 1,876

    Circulating PCSK9 as a sex-stratified predictor in primary prevention of cardiovascular disease: Insights from a prospective cohort study in Chinese adults

    American journal of preventive cardiology

More on Cardiovascular disease

Obesity

upin humans1

1 study
  1. PCSK9 is associated with obesity in humans (patients with type 2 diabetes).

    “Obese diabetic patients exhibit elevated oxi-LDL, soluble intercellular adhesion molecule-1, PCSK9, CD147 and CyPA levels.”

    Humanspatients with type 2 diabetes

    Circulating PCSK9: A new frontier in cancer risk stratification for obese diabetics

    Oncology letters

More on Obesity

Cancer occurrence

upin humans1

1 study
  1. PCSK9 predicts cancer occurrence in humans (obese individuals with type 2 diabetes) (AUC 0.726).

    “Receiver operating characteristic curve analysis identified PCSK9 as a potential predictor of cancer occurrence in obese individuals with T2DM [area under the curve (AUC)=0.726]”

    Humansobese individuals with type 2 diabetes

    Circulating PCSK9: A new frontier in cancer risk stratification for obese diabetics

    Oncology letters

More on Cancer occurrence

Alzheimer's disease

downin humans1HR 0.74

1 study
  1. PCSK9 is linked with a lower risk of Alzheimer's disease in APOE ε4 noncarriers (HR 0.74, 95% CI 0.58-0.94, p = 0.01).

    “Higher plasma PCSK9 protein levels were associated with a lower risk of AD (HR [95%CI]: 0.74 [0.58, 0.94]; p = 0.01) in APOE ε4 noncarriers”

    Humansin APOE ε4 noncarriers

    Blood PCSK9 Impacts Alzheimer's Disease Risk in an APOE Genotype-Dependent Manner: A Prospective Cohort Study

    Health science reports

More on Alzheimer's disease

Premature coronary artery disease

upin humans1

1 study
  1. Premature coronary artery disease is associated with PCSK9 in angiogram-proven premature CAD vs controls.

    “Lp(a) and PCSK9 levels were significantly higher in pCAD groups compared to controls.”

    Humansin angiogram-proven premature CAD vs controls

    Relationship between lipoprotein(a) and PCSK9 in angiogram-proven premature coronary artery disease in an Asian cohort

    Scientific reports

More on Premature coronary artery disease

Age

upin humans1

1 study
  1. PCSK9 is associated with age in humans.

    “Both in humans and rats, blood PCSK9 level correlated positively with increasing age”

    Humans

    PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction

    JACC. Basic to translational science

Liver fatty degeneration

upin rats1

1 study
  1. PCSK9 is associated with liver fatty degeneration in the rat model.

    “Age-related fatty degeneration of liver tissue positively correlated with serum PCSK9 levels in the rat model”

    Animalsin the rat modelliver

    PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction

    JACC. Basic to translational science

Intima-media thickness

upin humans1

1 study
  1. PCSK9 is associated with intima-media thickness in humans.

    “it correlated positively with intima-media thickness, a clinical parameter of CVD risk”

    Humans

    PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction

    JACC. Basic to translational science

More on Intima-media thickness

All 19

Funding

9 grants since 2017

National Heart, Lung, and Blood Institute$7.1MNational Institute of General Medical Sciences$1MGouvernement du Canada | Canadian Institutes of Health ResearchCA$1M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Higher PCSK9 is linked with lower Alzheimer’s disease risk in human APOE ε4 noncarriers, but no clear link appears in carriers. Cardiovascular associations point both ways: lower risk in men and higher risk in women, with no clear link in a highest-versus-lowest comparison in men. Human studies also associate higher PCSK9 with older age in men and postmenopausal status.

  2. Summary rewritten as its findings changed.

    As it read before

    Human studies link PCSK9 with age and pulse wave velocity and report higher plasma levels after menopause. A cohort links higher PCSK9 with higher cardiovascular disease risk in women but lower risk in men; comparing highest versus lowest levels in men shows no clear link. In a human trial, SYH2053 lowers PCSK9 in people with primary hypercholesterolemia or mixed dyslipidemia.

  3. Summary rewritten as its findings changed.

    As it read before

    PCSK9 has opposite cardiovascular risk associations in a human cohort: higher levels are linked with higher risk in women and lower risk in men, although a highest-versus-lowest comparison in men shows no clear link. Other human studies link PCSK9 with age and menopause; a trial reports lower levels with caloric restriction in women with morbid obesity.

  4. Summary rewritten as its findings changed.

    As it read before

    PCSK9 is linked with higher cardiovascular disease risk in women but lower risk in men initially free of cardiovascular disease in a human cohort. Postmenopausal women have higher plasma PCSK9 than premenopausal women, whose levels also vary across menstrual phases.

  5. Summary written from the findings.

Latest

Dec 2025: 5Jan 2026: 31Feb 2026: 33Mar 2026: 33Apr 2026: 2May 2026: 7Jun 2026: 12Jul 2026: 9Aug 2026: 30Sep 2026: 24Oct 2026: 66Nov 2026: 94346 papers in 12 months
Research Square

Compact gene editor enables efficient DNA editing in mice

Viral delivery of the editor in mice reduced a cholesterol-regulating protein by about 82% and LDL cholesterol by about 47%.Viral delivery of the editor in mice reduced a cholesterol-regulating protein by about 82% and LDL cholesterol by about 47%.

Preprint: mouse studyInterventions
AHA Scientific Sessions 2026 Abstract

Blood hormone adds to heart failure risk prediction in obesity

Over 13 years, heart failure developed in 9.69% of adults with obesity in the highest endotrophin group versus 3.12% in the lowest.Over 13 years, heart failure developed in 9.69% of adults with obesity in the highest endotrophin group versus 3.12% in the lowest.

Cohort · 7,728 peopleHeart failure

See all 469 papers on PCSK9